Sorrento Therapeutics, Inc.

OTCPK:SRNE.Q Lagerbericht

Marktkapitalisierung: US$60.4m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Sorrento Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wir verfügen derzeit nicht über ausreichende Analystenabdeckung, um Wachstum und Umsatz für Sorrento Therapeutics zu prognostizieren.

Wichtige Informationen

n/a

Wachstumsrate der Gewinne

n/a

EPS-Wachstumsrate

Biotechs Gewinnwachstum24.7%
Wachstumsrate der Einnahmenn/a
Zukünftige Eigenkapitalrenditen/a
Analystenabdeckung

None

Zuletzt aktualisiertn/a

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Seeking Alpha • Sep 29

Sorrento unit Scilex pre-emptively pays off remaining notes for $39.7M

Scilex, a unit of Sorrento Therapeutics (NASDAQ:SRNE), said Thursday it pre-emptively paid off and eliminated all remaining senior secured notes in an aggregate principal amount of $67.7M for cash payment of ~$39.7M. Scilex will go public through a merger with SPAC Vickers Vantage (VCKA), which is expected to close in Q4.
Seeking Alpha • Sep 15

Sorrento Sofusa drug delivery system shows promise vs subcutaneous injection in trial

Sorrento Therapeutics (NASDAQ:SRNE) said that patients with rheumatoid arthritis who received Amgen's (NASDAQ:AMGN) Enbrel (etanercept) though the company's Sofusa Lymphatic Drug Delivery System showed improvement in disease activity, compared to etanercept subcutaneous (under the skin) injections in a phase 1b trial. To be eligible for the trial, participants had to be on a stable dose of 50mg of etanercept and not responding adequately to the etanercept subcutaneous treatment, the company said in a Sept. 15 press release. Preliminary results suggested that all seven patients who had completed the first cohort of the study (12 weeks) achieved a significant improvement in their Rheumatoid Arthritis Disease Activity at 50% of the subcutaneous dose (25mg). The company wanted to test if Sofusa's biodistribution profile could improve clinical response, reduce the amount of drug required to achieve a response or both. Sorrento said it will present full data from the study at the at the ACR Convergence 2022 Conference on Nov. 13.
Seeking Alpha • Aug 31

Sorrento stock rises 13% on FDA fast track status for low back pain therapy SP-103

The U.S. Food and Drug Administration (FDA) granted fast track designation to Scilex's drug/device product candidate SP-103 to treat acute low back pain (LBP). Scilex — which is over 99.9% owned by Sorrento Therapeutics (NASDAQ:SRNE) — is developing SP-103 to be a non-opioid triple-strength, non-aqueous lidocaine topical system for acute LBP. "We are very pleased that the FDA has granted Fast Track designation for the non-opioid SP-103 program, the next generation triple strength formulation of ZTlido," said Scilex President and CEO Jaisim Shah. If approved, SP-103 could become the first FDA-approved lidocaine topical product to treat acute LBP, Scilex said in an Aug. 30 press release. Scilex is currently in the middle of a merger with SPAC Vickers Vantage I (NASDAQ:VCKA) and will go public on Nasdaq under the symbol SCLX. SRNE +13.40% to $2.20 premarket Aug. 31
Seeking Alpha • Aug 23

Sorrento achieves positive results in pivotal trial for abivertinib in NSCLC

Sorrento Therapeutics (NASDAQ:SRNE) said that a pivotal study of its candidate abivertinib in non-small cell lung cancer demonstrated an overall response rate of 56.5%. In addition, results showed that 11 patients had complete responses ("CR") for a CR rate of 5.3% and median overall survival of 28.2 months. The patients enrolled in the trial were heavily pretreated. Abivertinib, a third-generation EGFR inhibitor, selectively inhibits EGFR-activating and resistant mutations with ~300-fold greater potency as compared with wild-type EGFR. Sorrento (SRNE) said that due to the data, it is closing the study and preparing for a pre-New Drug Applicaiton meeting with the US FDA. Check out why Seeking Alpha contributor SimeOne Trading sees Sorrento (SRNE) as a hold.
Seeking Alpha • Aug 17

Sorrento's unit Scilex inks distribution deal for pain drug ZTlido with CH Trading

Sorrento's (NASDAQ:SRNE) unit Scilex Holding signed a distribution agreement for its non-opioid pain drug ZTlido with CH Trading Group, for certain territories including Middle East and North Africa. "We are pleased to work with CH Trading to help support us through the processes of obtaining global Halal certification as well as regulatory approval in the overseas designated territories," said Scilex CEO Jaisim Shah. Scilex is currently in the middle of a merger with SPAC Vickers Vantage I (NASDAQ:VCKA) and will go public on Nasdaq under the symbol SCLX.
Analyseartikel • Jul 22

Is Sorrento Therapeutics (NASDAQ:SRNE) A Risky Investment?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Seeking Alpha • Jul 15

Sorrento Therapeutics: The Enigma

Sorrento's outsized ambitions are not playing well for shareholders. Sorrento has assembled a significant group of COVID-19 assets that could perk up its value as the pandemic smolders ever hotter. Sorrento's performance has not lived up to its potential. Sorrento (SRNE) is an enigmatic company that has drawn my attention. It boasts a major pharma style pipeline. That is a blessing and a curse, as discussed below. Sorrento's growing share count is bad news for shareholders CEO's of publicly traded companies are an enthusiastic breed, none more so than Sorrento's CEO Henry Ji. Disappointingly, Dr. Ji abstains from providing quarterly earnings briefings. Seeking Alpha does however include a smattering (three) of presentations he has made in recent years at investor conferences. Most recently he presented at the 09/2021 Benzinga Healthcare Small Cap Conference. During this presentation he showed his outsized ambition for Sorrento. He responded as follows to the moderator's question on whether he remained confident as to his previous comment that Sorrento could be in the $100 billion market cap range over the next few years: My goal is to build a company $200 billion to $400 billion. And we think with the trajectory that Moderna has from $5 billion to $180 billion, it seems doable. We have the pipeline. We have a much bigger pipeline. And meanwhile, we are doing the vaccination, multivalent and our animal testing shows our multivalent strategy works much better than the current Washington or Wuhan-based vaccine. So that vaccine alone, if we develop it in Mexico, which we believe we are going to be able to testing 50,000 people very quickly, we will get that with potentially can come in here as a priority as a universal booster for antibody, take the Moderna, Pfizer's or J&J's, that could be a huge market, especially for developing country like Latin America, other places North America with local chance beautiful. In order to achieve big results one must have vision and goals. CEO Ji certainly has a vision and goals. In checking out Sorrento's latest available proxy statement with its summary compensation table, I was stunned to find the following from its 2021 proxy: Sorrento 2021 proxy summary compensation table (seekingalpha.com) Wow! That is some performance bonus approved at the annual meeting by shareholders in 10/2020. Footnote 4 to CEO Ji's $162 million option award reads as follows: (4) Includes $6,510,980 of grant date fair value attributable to the option to purchase 7,844,554 shares of common stock of Scilex Holding Company that Dr. Ji has agreed to forego and relinquish if it is not approved by our stockholders at the Annual Meeting (see Proposal 5). Also includes $150,317,148 of grant date fair value attributable to the CEO Performance Award, which was approved by our stockholders at our 2020 Annual Meeting of Stockholders held on October 16, 2020. The chart below showing Sorrento's price trajectory during 2020 and beyond reveals no apparent reason for such shareholder largesse: It does reveal a pattern of share count inflation coupled with dwindling share price. Sorrento boasts a large pipeline of molecules in trials for diverse indications Sorrento's pipeline covers multiple areas: COVID-19 (shown below), Immunotherapy (17 trials), Pain (6 trials), Lymphatic Delivery (3 trials), as shown in its website. It has one FDA approved therapy ZTLIDO 1.8%, (lidocaine topical system). Aside from COVID-19, the bulk of its trials are early stage. It lists the following as its phase 3/pivotal trials: FUJOVEE (Abivertinib) in treatment of NSCLC, PD-L1 (Socazolimab) in treatment of SCLC, PD-L1 (STI-3031) in treatment of Cervical Cancer, and SP-102 (SEMDEXA) in treatment of Lumbar Radicular/Sciatica Pain. Its COVID-19 pipeline covers a wide array of COVID-19 therapeutic modalities. Sorrento pipeline (sorrentotherapeutics.com) Sorrento issued an exciting press release on 06/24/2021 announcing that it had received an EUA in Mexico for its COVI-STIX. It described COVI-STIX as: ...a sensitive and rapid (approximately 15-minute) diagnostic test for the detection of the SARS-CoV-2 virus nucleocapsid antigen in nasal or nasopharyngeal samples of patients... It further announced that initial shipments were expected in July. Subsequently in 12/2021 it issued another release touting COVISTIX as a potentially best in class rapid COVID-19 virus antigen detection test. It noted that it was approved and marketed in Mexico and Brazil and was CE marked in Europe. In terms of production, it was constructing a facility to produce six (6) million COVISTIX tests per month in San Diego. It was also negotiating incentive packages with various states to further enhance production. It has capacity of 30 million COVISTIX tests per month on its near term horizon. Longer term it looks for a potential of a hundred million per month. Subsequently in 02/2022, Sorrento announced acquisition of majority interest with an option to acquire 100% of Zhengzhou Fortune Bioscience ("FortuneBio"). FortuneBio is a diagnostic product manufacturer with dozens of approved diagnostic products on the market.
Seeking Alpha • Jul 07

Sorrento Therapeutics subsidiary Scilex to acquire Ancora Medical

Scilex Holding Co., a subsidiary of  Sorrento Therapeutics (NASDAQ:SRNE), is acquiring privately held medtech Ancora Medical. Ancora's key asset is its Nerve Block Catheter Set for surgical pain management during the pre-operative, perioperative and post-operative periods associated with general and orthopedic surgery. Doctors use the device to locate peripheral nerves. Financial terms were not disclosed. The companies said the worldwide peripheral nerve block catheter market is estimated to exceed $740.7M by 2027. Sorrento (SRNE) is viewed as a hold by Seeking Alpha's Quant rating with poor grades for valuation, growth, and profitability.
Seeking Alpha • Mar 15

Sorrento Therapeutics: Sales Are Up But EY Identifies Internal Control Issues

Sorrento Therapeutics' revenues are up 33% year-on-year. The Company recently received orders for its COVISTIX. Sorrento Therapeutics has acquired Fortune Bioscience and Virex Health.
Seeking Alpha • Oct 09

Sorrento Therapeutics: Wide Oncology Pipeline, And Watch Out For COVID Updates

First, a striking point about Sorrento Therapeutics is that despite its $1.93 billion market cap, it possesses a wide pipeline, similar to the biggest biopharmaceuticals. Second, it is also generating revenues mainly from a prescription drug and has been able to get EUA approval for COVISTIX testing kits, a space that should be closely watched by investors before investing. On the other hand, it is spending colossal amounts on clinical development, has debts with limited cash at hand. Not possessing any first-mover advantage, its anti-COVID therapies still matter given the prevalence of highly infectious variants and the time-limited protection conferred by vaccines. Analyzing the pipeline, there are assets which the company could monetize in the worst-case scenario that finances cannot be raised to fund promising oncology operations or service debt.

In diesem Abschnitt stellen wir normalerweise Umsatz- und Gewinnwachstumsprognosen vor, die auf den Konsensschätzungen professioneller Analysten basieren, um den Anlegern zu helfen, die Fähigkeit des Unternehmens zur Gewinnerzielung zu verstehen. Da Sorrento Therapeutics jedoch nicht genügend Daten aus der Vergangenheit zur Verfügung gestellt hat und keine Analystenprognose vorliegt, können die zukünftigen Erträge nicht zuverlässig durch Extrapolation von Vergangenheitsdaten oder anhand von Analystenprognosen berechnet werden.

Dies ist eine recht seltene Situation, da 97 % der von SimplyWall St erfassten Unternehmen über Finanzdaten aus der Vergangenheit verfügen.

Gewinn- und Umsatzwachstumsprognosen

OTCPK:SRNE.Q - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
6/30/202364-548-252-235N/A
3/31/202361-672-279-260N/A
12/31/202263-573-316-294N/A
9/30/202260-494-344-298N/A
6/30/202255-524-364-320N/A
3/31/202257-472-362-317N/A
12/31/202153-428-326-282N/A
9/30/202151-355-269-251N/A
6/30/202151-320-252-210N/A
3/31/202147-231-211-169N/A
12/31/202040-298-199-160N/A
9/30/202042-290-185-155N/A
6/30/202036-270-165-158N/A
3/31/202033-249-173-167N/A
12/31/201931-292-184-173N/A
9/30/201925-279-197-182N/A
6/30/201924-262-183-157N/A
3/31/201921-279-158-132N/A
12/31/201821-204-133-112N/A
9/30/201835-105-129-112N/A
6/30/2018152-60-111-104N/A
3/31/20181530-108-101N/A
12/31/20171529-110-99N/A
9/30/2017135-57-83-71N/A
6/30/201716-39-92-80N/A
3/31/201712-68N/A-73N/A
12/31/20168-61N/A-71N/A
9/30/20165-67N/A-71N/A
6/30/20164-83N/A-67N/A
3/31/20165-51N/A-53N/A
12/31/20155-46N/A-42N/A
9/30/20154-31N/A-34N/A
6/30/20154-38N/A-21N/A
3/31/20154-35N/A-28N/A
12/31/20144-35N/A-29N/A
9/30/20143-37N/A-28N/A
6/30/20142-33N/A-26N/A
3/31/20141-29N/A-23N/A
12/31/20130-22N/A-16N/A
9/30/20130-12N/A-11N/A
6/30/20131-10N/A-9N/A
3/31/20131-6N/A-5N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: Unzureichende Daten, um festzustellen, ob das prognostizierte Gewinnwachstum von SRNE.Q über der Sparquote liegt (2.2%).

Ertrag vs. Markt: Unzureichende Daten, um festzustellen, ob die Gewinne von SRNE.Q schneller wachsen werden als der Markt US

Hohe Wachstumserträge: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von SRNE.Q in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von SRNE.Q schneller wachsen werden als der Markt von US.

Hohe Wachstumseinnahmen: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Einnahmen von SRNE.Q schneller wachsen werden als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von SRNE.Q in 3 Jahren voraussichtlich hoch sein wird

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2024/01/04 23:57
Aktienkurs zum Tagesende2024/01/03 00:00
Gewinne2023/06/30
Jährliche Einnahmen2022/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Sorrento Therapeutics, Inc. wird von 9 Analysten beobachtet. dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Raghuram SelvarajuAegis Capital Corporation
James MolloyAlliance Global Partners
Mayank MamtaniB. Riley Securities, Inc.